BACKGROUND: Cutaneous squamous cell carcinoma (CSCC) is a very common malignancy in which most patients present with localized disease. Recurrent and metastatic disease is rare, and there is no standard therapy. These tumors frequently overexpress the epidermal growth factor receptor (EGFR). We conducted a phase 2 trial to determine the response rate to therapy with erlotinib, an EGFR tyrosine kinase inhibitor, in patients with locoregionally recurrent or metastatic CSCC that was not amenable to curative treatment (NCT01198028). METHODS: Eligible patients had CSCC not amenable to curative intent therapy. Patients who had previously received anti-EGFR targeted therapy were excluded. All patients received oral therapy with erlotinib 150 mg daily. Response was assessed every 8 weeks, and treatment continued until progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was overall response rate according to RECIST 1.1 criteria. RESULTS: A total of 39 patients received treatment during the trial; 29 of these patients were evaluable for response. The overall response rate was 10% (3/29); all responses were partial responses. The disease control rate (partial response 1 stable disease) was 72% (21/29). The median progression-free survival was 4.7 months (95% confidence interval, 3.5-6.2 months); the median overall survival was 13 months (95% confidence interval, 8.4-20.5 months). No unexpected toxicities were seen. CONCLUSION: Erlotinib therapy was feasible for most patients with incurable CSCC and was associated with expected toxicities. However, only a modest response rate of 10% was observed. Further study of EGFR tyrosine kinase inhibitors in this patient population is not warranted. Cancer 2018;124:2169-73.
INTRODUCTION
In the United States, over 3 million nonmelanoma skin cancers are diagnosed yearly, and the incidence is increasing. 1 Cutaneous squamous cell carcinoma (CSCC) represents approximately one-fifth of these cases and is the second most common human cancer after basal cell carcinoma. 2 In the majority of cases, these tumors can be managed effectively with local therapy, but approximately 4% of patients develop nodal disease, and 1.5% die of their disease. 3 Increasing tumor bulk, depth of invasion, poorly differentiated or variant histology, perineural spread, and involved surgical margins are predictors of tumor recurrence and disease-specific mortality. 4 Moreover, CSCCs arising in a burn site or from severely injured or chronically diseased skin have a high rate of metastases, approaching 40% at 5 years. 2 Patients who are chronically immunosuppressed, either from a disease such as chronic lymphocytic leukemia or immunosuppressive medications taken after organ transplantation, are at higher risk of developing aggressive CSCC. 5 For patients with disease not amenable to curative intent therapy, treatment options are limited. Cisplatin-based regimens have relatively high response rates [6] [7] [8] ; however, therapy is often poorly tolerated in this population of patients who are often elderly and suffer from comorbid illnesses. Targeted therapies have been studied, especially those targeting the epidermal growth factor receptor (EGFR), which is frequently overexpressed in cutaneous squamous cell carcinoma. 9 Our previous research studied gefitinib, a small molecule tyrosine kinase inhibitor with activity against EGFR, in patients with locally advanced cutaneous CSCC. 10 Twenty-three patients received oral gefitinib 250 mg daily for up to 60 days before definitive treatment with surgery, radiation, or a combination of the two. The response rate was 45%, and 4 patients (18%) had a complete response. Treatment was well tolerated; rash and diarrhea were the most common adverse effects. In unresectable disease, response rates to gefitinib were low (11%), but 38% of patients had stable disease after 8 weeks of therapy. 11 Cetuximab, an anti-EGFR antibody, has also been studied in this disease in a phase 2 trial. 12 Thirty-six patients with unresectable CSCC were treated with cetuximab weekly. The response rate in this study was 28%. Cetuximab is listed in the National Comprehensive Cancer Network compendium as a therapy for recurrent/metastatic CSCC.
Gefitinib was initially approved by the US Food and Drug Administration for advanced non-small cell lung cancer in 2003, but approval was withdrawn in 2005 after postmarketing studies failed to confirm the clinical benefit seen in initial studies. 13, 14 Because gefitinib was no longer commercially available, our study was performed using the closely related EGFR tyrosine kinase inhibitor erlotinib. Erlotinib 150 mg daily was more effective than gefitinib 250 mg daily in patients with non-small cell lung cancer not selected for EGFR mutation and is thought to be more active against wild-type EGFR. 13, 15 Thus, we believed it was important to establish the efficacy of erlotinib monotherapy with a phase 2 single-arm trial in patients with CSCC not amenable to curative intent therapy.
MATERIALS AND METHODS

Study Design and Objectives
This trial was an open-label, uncontrolled, single-center phase 2 study conducted at The University of Texas MD Anderson Cancer Center. The primary endpoint was to determine the overall response rate (complete response or partial response) to treatment with erlotinib in patients with locoregionally recurrent or metastatic CSCC.
Secondary endpoints were duration of response, duration of stable disease, progression-free survival, overall survival, and safety and tolerability.
Patient Eligibility
Eligible patients had histologically or cytologically confirmed CSCC that was not amenable to curative intent therapy, with either distant metastases or locoregional disease for which curative resection or definitive radiation were not feasible. Measurable disease, age of at least 18 years, Eastern Cooperative Oncology Group performance status 0-2, and adequate organ and marrow function were required. One prior systemic therapy was allowed. Patients who had received prior EGFR inhibitor therapy and those with other invasive malignancy within the past 3 years were excluded. Patients with pulmonary fibrosis, chronic liver disease, or active disorders affecting gastrointestinal motility or absorption were also excluded. Patients with a history of organ transplantation and those on immunosuppression for autoimmune disease were eligible as long as they met criteria for organ function and were not receiving cytotoxic treatment (eg, methotrexate). Patients with chronic lymphocytic leukemia were excluded. All patients gave written informed consent, and the protocol was approved by the MD Anderson Clinical Research Committee and Institutional Review Board.
Study Treatment
All patients received oral erlotinib 150 mg daily on continuous 28 day cycles. Patients could continue treatment until disease progression. Dose reductions and management of expected toxicities were specified in the protocol. Therapy was discontinued if patients were unable to recover from toxicities despite dosing interruption up to 14 days or if patients were unable to tolerate erlotinib at a 50 mg/day dose.
Study Assessments
All patients underwent pretreatment screening within 14 days prior to starting therapy including medical history, physical examination, assessment of performance status, and laboratory testing. Baseline imaging was performed within 28 days prior to the start of treatment. Tumor response was assessed according to RECIST 1.1 criteria every 8 weeks until progression. 16 Toxicity was evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0). Serious adverse events were reported to the MD Anderson IRB and to the sponsor.
Statistical Analyses
Descriptive statistics including mean, standard deviation, median, and range for continuous variables (eg, age) were provided. Frequency counts and percentages for categorical variables (eg, sex and race) were provided. The Kaplan-Meier method was used for time-to-event analysis, including progression-free survival and overall survival. The median time to event in months and the 95% confidence interval were calculated. Statistical software SAS 9.3 (SAS, Cary, North Carolina), S-Plus 8.2 (TIBCO Software Inc., Palo Alto, California) and R were used for all the analyses.
RESULTS
A total of 39 patients were enrolled in the study and treated between April 2011 and June 2014. Ten patients received < 4 weeks of therapy and were not reimaged; these patients were deemed not evaluable for response. Five patients discontinued due to toxicity, 2 by patient/ investigator choice, and 3 due to early death not thought to be related to study drug. These 10 patients were included in toxicity and survival analyses only.
Original Article
Patient Characteristics
The demographics for the 39 patients treated on this study are shown in Table 1 . The majority of patients were men (87%) and were non-Hispanic white (95%). Most patients (72%) were aged > 65 years. Primary sites were in heavily sun-exposed areas (scalp, face, lip, distal extremity) in 90% of patients; 3 patients had primary sites on the trunk and 1 patient had a primary site on the thigh. No organ transplant recipients enrolled in the trial. All but 1 patient had received prior surgery for CSCC, and most patients (82%) had also received prior radiation therapy. The predominant pattern of recurrent disease was locoregional. Of 16 patients who had received prior chemotherapy, 12 had platinum agents with radiation, 1 had neoadjuvant therapy, and 3 had chemotherapy for recurrent disease.
Exposure to Erlotinib
The median duration of erlotinib treatment was 98 days (range, 1-526 days). The most common reason for discontinuation was clinical or radiographic progression (28 patients [72%]). Five patients (13%) discontinued therapy secondary to toxicity, and 3 patients (8%) withdrew consent.
Response to Therapy
Twenty-nine patients completed 4 weeks of therapy and were considered evaluable for response. Of those patients, 3 (10%) had a confirmed partial response, 18 (62%) had stable disease, and 8 (28%) had progressive disease as the best overall response according to RECIST 1.1 criteria. The disease control rate was 72%. All 3 patients with partial response had prior chemotherapy: 2 received carboplatin with radiation and 1 had paclitaxel and carboplatin front-line for recurrent disease. The 3 patients who responded to treatment remained on therapy for 4.6, 5.3, and 13.2 months before developing progression. The median duration of stable disease was 7.2 months (range, 1.6-41.4 months).
Progression-Free and Overall Survival
For the 39 patients who received treatment during the study, the median progression-free survival was 4.7 months (95% confidence interval, 3.5-6.2 months); 14% of patients were alive and without progression at 1 year. The median overall survival was 13 months (95% confidence interval, 8.4-20.5 months). The 1-year overall survival rate was 53% and 3-year overall survival rate was 19% ( Fig. 1 ).
Safety and Tolerability
Adverse events were reported for all 39 patients who enrolled in the study ( Table 2 ). The most common toxicities were acneiform rash (64%) and fatigue (46%). Most toxicities were grade 1 and 2. There were no grade 4 or 5 treatment-related adverse events; grade 3 adverse events were fatigue (4 patients [10%]), acneiform rash (3 patients [8%]), dehydration (1 patient [3%]), and syncope (1 patient [3%]). Adverse events were consistent with those seen in prior trials with erlotinib. Seven patients died during therapy or within 30 days of the final dose of erlotinib. None of these deaths were thought to be related to treatment; underlying disease was thought to be a major factor in all deaths.
DISCUSSION
In our phase 2 study of erlotinib in patients with recurrent or metastatic CSCC, modest response rates (10%) were seen. Overall response rate and median progression-free survival (4.7 months) were similar to those seen in similar patients treated with gefitinib. 11 Cetuximab had a higher response rate in a phase 2 study (28%) but a similar median progression-free survival (4.1 months); however, this trial did not allow patients with prior systemic therapy. 12 In our study, no unexpected toxicities were seen, although 13% of patients discontinued therapy due to toxicity, suggesting that systemic therapy, even with generally well-tolerated EGFR tyrosine kinase inhibitors, can be toxic in this patient population, where many patients are elderly and have significant comorbidities.
Novel therapies are urgently needed for these patients. Our group has shown that these tumors tend to have a high mutational burden; 17 and increasing mutational burden has been linked to responsiveness to immunotherapy in other malignancies. 18, 19 Case reports suggest that patients with incurable CSCC may benefit from checkpoint inhibitors such as nivolumab or pembrolizumab. 20, 21 In 26 patients with CSCC in an expansion cohort of a phase 1 trial of PD-1 inhibitor REGN2810, a response rate of 52% was observed. 22 Phase 2 trials are currently ongoing with the PD-1 inhibitors pembrolizumab (NCT02964559) and REGN2810 (NCT02760498) in unresectable or metastatic CSCC. 20, 21 Immunotherapy is likely to play a major role in treatment of this disease in the future.
In conclusion, our study demonstrates that erlotinib has modest activity in incurable CSCC, similar to previous results with gefitinib. The activity of immune checkpoint inhibitors in early phase trials is encouraging, supporting further research with these agents for patients with aggressive high-risk CSCC.
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